|
Active substance |
Fremanezumab (TEV-48125) |
|
Holder |
Teva Pharmaceuticals Europe |
|
Status |
Closed |
|
Indication |
patients with episodic migraine or chronic migraine who have successfully completed (per protocol) Study TV48125‐CNS‐30051 or the treatment phase of Study TV48125‐CNS‐30068. |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
11/05/2021 |
Fremanezumab (TEV-48125)
Last updated on 13/09/2024